Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

被引：0

作者：

Alex Diamantopoulos

A. Finckh

T. Huizinga

D. K. Sungher

L. Sawyer

D. Neto

F. Dejonckheere

机构：

[1] Symmetron Limited,Rheumatology

[2] Kinetic Centre,Rheumatology

[3] University Hospitals of Geneva,undefined

[4] Leiden University Medical Center,undefined

[5] F. Hoffmann-La Roche,undefined

来源：

PharmacoEconomics | 2014年 / 32卷

关键词：

Palliative Care; Juvenile Idiopathic Arthritis; Tocilizumab; Visual Analogue Scale Pain; Health Assessment Questionnaire;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：775 / 787

页数：12

共 50 条

[41] A COST-EFFECTIVENESS ANALYSIS OF ABATACEPT, TOCILIZUMAB, AND TNF-INHIBITOR COMPARED WITH RITUXIMAB AS A SECOND-LINE THERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS
Huoponen, S.
Aaltonen, K. J.
Joensuu, J. T.
Rutanen, J.
Relas, H.
Taimen, K.
Puolakka, K.
Sokka, T.
Nordstrom, D.
Blom, M.
VALUE IN HEALTH, 2016, 19 (07) : A538 - A538
[42] COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA) PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TNF TREATMENT IN TURKEY
Ertenli, I
VALUE IN HEALTH, 2012, 15 (07) : A445 - A445
[43] Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis (RA) in the UK.
Brennan, A
Bansback, N
Conway, P
Reynolds, AV
ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S157 - S157
[44] Cost-effectiveness of valdecoxib compared to diclofenac in patients with rheumatoid arthritis (RA) in the UK (UK) and Germany
Alten, RH
von Scheele, B
Gaffney, L
Maciver, F
Niculescu, L
VALUE IN HEALTH, 2004, 7 (06) : 664 - 664
[45] ABATACEPT OR INFLIXIMAB FOR RHEUMATOID ARTHRITIS IN VENEZUELA? A COST-EFFECTIVENESS ANALYSIS
Alfonso-Cristancho, R.
Serra, N.
Aiello, E. C.
Roa, C. N.
VALUE IN HEALTH, 2011, 14 (03) : A126 - A127
[46] COST-EFFECTIVENESS OF TOCILIZUMAB COMPARED TO STANDARD THERAPEUTIC SEQUENCES FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) PATIENTS IN PORTUGAL
Diamantopoulos, A.
Andrade, S.
Bernardo, A.
Branco, J.
Ines, L.
Pereira da Silva, J. A.
Santos, M. J.
Monteiro, I
VALUE IN HEALTH, 2011, 14 (07) : A307 - A307
[47] Cost-effectiveness analysis of etanercept vs infliximab for treatment of severe rheumatoid arthritis in Brazil
Saggia, M. G.
Pina, F. P.
VALUE IN HEALTH, 2006, 9 (06) : A220 - A220
[48] The cost-effectiveness analysis of celecoxib and NSAIDs with gastroprotective agents for treatment of rheumatoid arthritis in Ukraine
Zaliska, O
VALUE IN HEALTH, 2002, 5 (06) : 475 - 475
[49] A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
Choi, HK
Seeger, JD
Kuntz, KM
ARTHRITIS AND RHEUMATISM, 2000, 43 (10): : 2316 - 2327
[50] Cost-effectiveness of rituximab strategies in rheumatoid arthritis
Seror, Raphaele
Mariette, Xavier
LANCET, 2017, 389 (10067): : 365 - 366

← 1 2 3 4 5 →